Nodal burden predicts higher preoperative ctHPVDNA levels, while aggressive pathologic features paradoxically correlate with ...

SCLC, addressing a high-relapse setting with limited second-line efficacy and modest survival benefit. Ifinatamab deruxtecan ...

O'Cearbhaill, MD, of Memorial Sloan Kettering Cancer Center discussed the rationale and early progress of a phase 1/2 ...

AZD0120, a rapidly manufactured CAR T product, was used successfully in a small number of patients with multiple myeloma with ...

PRO-XTEN dual masking aims to keep the engager inactive in circulation, activate within tumor protease-rich microenvironments ...

FDA acceptance positions 18F-FET as a potential first-in-class US-approved amino acid PET agent for glioma characterization, addressing a major posttreatment imaging specificity gap.

DNADX high scores predicted improved PFS, supporting genomic instability and DNA repair deficiency as biologically relevant ...

Sofetabart mipitecan (LY4170156), an investigational folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC), elicited strong antitumor activity in patients with recurrent ...

Trastuzumab pamirtecan, a novel antibody-drug conjugate, showed initial efficacy signals in pretreated patients with ...

Updated findings from the phase 3 ROSELLA trial (NCT05257408) showed that combining relacorilant (Lifyorli) with ...

KEYNOTE-564 follow-up shows OS and DFS gains with adjuvant pembrolizumab in high-risk ccRCC, plus guidance on relapse after therapy. In the adjuvant setting, managing the patient with high-risk clear ...

Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and ...